Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer
Open Access
- 1 August 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 93 (15), 1141-1146
- https://doi.org/10.1093/jnci/93.15.1141
Abstract
Background: Only 25% of patients with HER-2/neu-positive metastatic breast tumors respond favorably to trastuzamab (Herceptin) treatment. We hypothesized that a high failure rate of patients on trastuzamab could result if some of the metastases were HER-2 negative and these metastases ultimately determine the course of the disease. Methods: We used tissue microarrays (TMAs) containing four samples each from 196 lymph node-negative primary tumors, 196 lymph node-positive primary tumors, and three different lymph node metastases from each lymph node-positive tumor to estimate HER-2 gene amplification by fluorescence in situ hybridization (FISH) and Her-2 protein overexpression by immunohistochemistry (IHC). Results: FISH and IHC analyses gave the same result with respect to HER-2 status for 93.7% of the tissues contained in the TMAs. Tissue samples were, therefore, considered to be HER-2 positive if they were positive for either HER-2 DNA amplification or Her-2 protein expression and HER-2 negative if both FISH and IHC gave a negative result. The HER-2 status of lymph node-positive primary tumors was maintained in the majority of their metastases. For HER-2-positive primary tumors, 77% (95% confidence interval [CI] = 59% to 90%) had entirely HER-2-positive metastases, 6.5% (95% CI = 8% to 21%) had entirely HER-2-negative metastases, and 16.3% (95% CI = 5% to 34%) had a mixture of HER-2-positive and HER-2-negative metastases. For HER-2-negative primary tumors, 95% (95% CI = 88% to 98%) had metastases that were entirely negative for HER-2. Conclusions: Our data suggest that differences in HER-2 expression between primary tumors and their lymph node metastases cannot explain the high fraction of nonresponders to trastuzamab therapy.Keywords
This publication has 26 references indexed in Scilit:
- erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast CancerJNCI Journal of the National Cancer Institute, 1998
- The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 casesBreast Cancer Research and Treatment, 1995
- Immunohistochemical detection ofHER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosisCancer, 1995
- Prognostic significance of c-erbB-2 expression in node negative breast cancerBritish Journal of Cancer, 1993
- Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.Journal of Clinical Oncology, 1992
- Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.Journal of Clinical Oncology, 1992
- C-erbb-2 oncoprotein expressionversus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancerCancer, 1992
- Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.Journal of Clinical Oncology, 1992
- Prognostic significance of her‐2/neu expression in breast cancer and its relationship to other prognostic factorsInternational Journal of Cancer, 1991
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989